🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 5 of 28

  1. A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab)

    Boehringer Ingelheim

    advanced solid tumors

    phase 1 other active

    1 trial

  2. A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps

    Boehringer Ingelheim

    Melanoma, Solid tumours

    phase 1 other active

    1 trial

  3. A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab

    Boehringer Ingelheim

    unresectable advanced or metastatic solid cancer

    phase 1 other active

    1 trial

  4. A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor

    Boehringer Ingelheim

    Solid cancer tumors

    phase 1 other active

    1 trial

  5. A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer, gastroesophageal junction cancer, or pancreatic cancer

    Astellas Pharma GmbH

    Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  6. A study of ASP3082 in adults with advanced solid tumors

    Astellas Pharma GmbH

    Solid Tumor

    phase 1 other active

    1 trial

  7. A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors.

    Eli Lilly Co.

    Advanced Breast Cancer and Other Solid Tumors

    phase 1 other active

    1 trial

  8. A study of different dose levels of FluBHPVE6E7 or placebo in women infected with the virus Human Papilloma Type 16 (HPV 16).

    Blue Earth Diagnostics Ireland Ltd

    Treatment of human papilloma virus (HPV) associated infections, precancers and cancers

    phase 1 other active

    1 trial

  9. A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC)

    Astellas Pharma GmbH

    Locally advanced or metastatic NSCLC

    phase 1 other active

    1 trial

  10. A study of safety and efficacy of novel targeted therapy combinations in adult patients with advanced or metastatic colorectal cancer.

    Novartis Pharmaceuticals

    Advanced or metastatic BRAF V600 colorectal cancer.

    phase 1 other active

    1 trial

  11. A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors.

    Eli Lilly Co.

    Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.

    phase 1 other active

    1 trial

  12. A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer

    The George Institute

    Refractory metastatic Her2 positive breast cancer

    phase 1 other active

    1 trial

  13. A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12)

    Arcus Biosciences

    Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer

    phase 1 other active

    1 trial

  14. A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.

    Bayer AG

    Prostate cancer

    phase 1 other active

    1 trial

  15. A study to assess safety and efficacy of SOT201 in patients with advance/metastatic cancer

    IO Biotech

    advanced/metastatic solid tumors

    phase 1 other active

    1 trial

  16. A study to assess the effect of CC-95251 alone and in combination with anti-cancer drugs in subjects with Acute Myeloid Leukemia and Myelodysplastic Syndromes

    Celgene Europe Limited

    Acute Myeloid Leukemia and Myelodysplastic Syndromes

    phase 1 other active

    1 trial

  17. A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT

    The George Institute

    Advanced epithelial tumors and immune checkpoint blockade (ICB) resistant solid tumors

    phase 1 other active

    1 trial

  18. A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors.

    Eli Lilly Co.

    KRAS G12D-mutant solid tumors.

    phase 1 other active

    1 trial

  19. A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors

    Eli Lilly Co.

    Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.

    phase 1 other active

    1 trial

  20. A study to compare Onivyde manufactured at two different production sites in adult participants with advanced cancer in the pancreas

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  21. A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas

    Hoffmann-La Roche

    Small Cell Lung Cancer and Neuroendocrine Carcinoma

    phase 1 other active

    1 trial

  22. A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia

    Incyte

    Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  23. A study to find a suitable dose of ASP5834 in adults with solid tumors

    Astellas Pharma GmbH

    Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification

    phase 1 other active

    1 trial

  24. A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy

    Boehringer Ingelheim

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 1 other active

    1 trial

  25. A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

    Oncopeptides AB (publ)

    Recurrent glioblastoma

    phase 1 other active

    1 trial

  26. A study to investigate the safety and tolerability of Trastuzumab Deruxtecan in combination with Immunotherapy Agents with and without chemotherapy, as the first treatment option for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer.

    AstraZeneca AB

    Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)

    phase 1 other active

    1 trial

  27. A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers

    Janssen-Cilag International N.V.

    Previously treated lymphoma (blood cancer) or solid tumors and NHL

    phase 1 other active

    1 trial

  28. A study to learn BAY 3498264 when given alone or together with sotorasib in participants who have advanced solid cancers with specific genetic changes called KRASG12C mutation

    Bayer AG

    Advanced solid tumors harboring KRAS G12C mutation

    phase 1 other active

    1 trial

  29. A study to learn about the study medicine called PF-08046032 in people with advanced cancers.

    Pfizer Australia Pty Ltd

    Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)

    phase 1 other active

    1 trial

  30. A study to learn how safe and tolerable odronextamab and cemiplimab are in adult patients with B-cell malignancies

    Lacuna Pharma Pty Ltd

    B-Cell Non-Hodgkin’s Lymphoma (B-NHL)

    phase 1 other active

    1 trial

  31. A study to learn how safe the study drug BAY 2416964 (AhR inhibitor) in combination with the treatment pembrolizumab is, how this combination affects the body, the maximum amount that can be given, how it moves into, through and out of the body and its action against advanced solid cancers in adults

    Bayer AG

    Advanced solid tumors

    phase 1 other active

    1 trial

  32. A study to see how combination of RMC-6291 and RMC-6236 is tolerated in multiple different dosages in participants with Advanced KRASG12C-mutated Solid Tumors

    Revolution Medicines

    Participants with Advanced KRASG12C-Mutated Solid Tumors

    phase 1 other active

    1 trial

  33. A study to test Aumolertinib in European participants with genetically linked advanced Lung Cancer

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations, Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations

    phase 1 other active

    1 trial

  34. A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer

    Boehringer Ingelheim

    Advanced head and neck cancer

    phase 1 other active

    1 trial

  35. A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.

    Boehringer Ingelheim

    solid tumour harbouring G12C mutation

    phase 1 other active

    1 trial

  36. A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).

    Boehringer Ingelheim

    solid tumors

    phase 1 other active

    1 trial

  37. A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    advanced, unresectable and/or metastatic solid tumors

    phase 1 other active

    1 trial

  38. A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas

    Boehringer Ingelheim

    colorectal carcinoma (CRC)

    phase 1 other active

    1 trial

  39. A study to test different doses of obrixtamig (BI 764532) in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.

    Boehringer Ingelheim

    Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

    phase 1 other active

    1 trial

  40. A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced solid tumours

    phase 1 other active

    1 trial

  41. A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    phase 1 other active

    1 trial

  42. A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and neck cancer or liver cancer

    Boehringer Ingelheim

    head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma

    phase 1 other active

    1 trial

  43. A study to test whether treatment with BI 770371 in combination with pembrolizumab with or without cetuximab helps people with head and neck cancer compared with pembrolizumab alone

    Boehringer Ingelheim

    Head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

  44. A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

    CureVac AG

    metastatic squamous non-small cell lung cancer

    phase 1 other active

    1 trial

  45. A trial to learn how ceralasertib affects the way certain medications move throughout the body over time and how safe it is to use ceralasertib with these medications in adults with advanced solid tumors

    AstraZeneca AB

    Advanced solid tumour

    phase 1 other active

    1 trial

  46. A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with ovarian, peritoneal, or fallopian tube cancer

    AstraZeneca AB

    Ovarian cancer Primary peritoneal cancer Fallopian tube cancer

    phase 1 other active

    1 trial

  47. A trial to learn how saruparib works and how safe it is in the bodies of adults with advanced solid tumors

    AstraZeneca AB

    advanced solid malignancies

    phase 1 other active

    1 trial

  48. A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people with solid tumors

    AstraZeneca AB

    Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.